Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02392325 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
A Phase 1 study of Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02392325 is a Phase 1 study of Dengue that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 12 participants, below the 3,980-participant average among 9 other Dengue trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02392325, a Phase 1 study of Dengue, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Dengue viruses infect millions of people throughout the tropics and subtropics each year. The development of a dengue vaccine is an important health priority. This study will evaluate the immunologic and clinical response to two dengue vaccines, given 9 months apart, in healthy adults with no history of previous flavivirus infection.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL rDEN1Δ30
- BIOLOGICAL rDEN2Δ30-7169
Study Locations (1)
Maryland
- Center for Immunization Research, Johns Hopkins School of Public Health - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02392325
The ClinicalTrials.gov registry entry for NCT02392325 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,980-participant average among 9 other Dengue trials with a reported enrollment target (100% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02392325 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02392325 about?
NCT02392325 is a clinical study titled "Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults". Dengue viruses infect millions of people throughout the tropics and subtropics each year. The development of a dengue vaccine is an important health priority. This study will evaluate the immunologic and clinical response to two dengue vaccines, given 9 months apart, in healthy adults with no histor...
What is the current status of trial NCT02392325?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-03. Estimated completion is 2017-02.
What conditions does trial NCT02392325 study?
This clinical trial studies the following conditions: Dengue.
What interventions are being tested in trial NCT02392325?
The interventions under investigation include: Placebo (BIOLOGICAL), rDEN1Δ30 (BIOLOGICAL), rDEN2Δ30-7169 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02392325?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02392325 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dengue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
COMPLETED · Phase 1
-
TDENV PIV and LAV Dengue Prime-boost Strategy
COMPLETED · Phase 1
-
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
COMPLETED · Phase 1
-
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
COMPLETED · Phase 1
-
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
COMPLETED · Phase 1
-
Tetravalent Chimeric Dengue Vaccine Trial
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.